{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-26-000062","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2026-05-20T11:14:07+00:00","discovered_at":"2026-05-20T11:15:00.234160+00:00","generated_at":"2026-05-20T11:16:02.795515+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunovant posts $0.73/sh Q4 loss; IMVT-1402 hits 72.7% ACR20 in D2T RA at Week 16","bullets":["IMVT-1402 in D2T RA: 72.7% ACR20, 54.5% ACR50, 35.8% ACR70 at Week 16; open-label, blinded assessors; safety well-tolerated.","Cash $902.1M as of Mar 31, 2026; provides runway to potential launch of IMVT-1402 in GD.","Net loss Q4 FY2026 $147.9M ($0.73/share) vs $106.4M ($0.64/share) YoY; FY net loss $505.6M ($2.77/share).","Batoclimab discontinued after Phase 3 TED miss; $39M contract cost recognized in Q4.","CLE proof-of-concept fully enrolled; topline data expected H2 2026. Other trials on track for GD, MG, CIDP, SjD."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-26-000062","json":"https://secwatch.observer/filing/0001764013-26-000062.json","markdown":"https://secwatch.observer/filing/0001764013-26-000062.md","text":"https://secwatch.observer/filing/0001764013-26-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/0001764013-26-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/imvt-20260520.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T11:16:02.795515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d2884424267714581c5d4d81e878751566b9c57","claim":"Immunovant, Inc. reported fourth quarter and fiscal year ended March 31, 2026 results: net income $147.9 million ($0.73 per common share), EPS ($0.73 per common share).","evidence_excerpt":"Net loss was $147.9 million ($0.73 per common share) for the three months ended March 31, 2026, compared to $106.4 million ($0.64 per common share) for the three months ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/0001764013-26-000062-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended March 31, 2026"},{"label":"Net income","value":"$147.9 million ($0.73 per common share)"},{"label":"EPS","value":"($0.73 per common share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}